Edition:
United States

Repros Therapeutics Inc (RPRX.PH)

RPRX.PH on Philadelphia Stock Exchange

1.20USD
17 Feb 2017
Change (% chg)

$0.05 (+4.35%)
Prev Close
$1.15
Open
$1.20
Day's High
$1.20
Day's Low
$1.20
Volume
300
Avg. Vol
655
52-wk High
$3.44
52-wk Low
$0.81

Latest Key Developments (Source: Significant Developments)

Repros announces new CEO
Thursday, 2 Feb 2017 09:15am EST 

Repros Therapeutics Inc : Repros announces new CEO . Says ceo and president Joseph S. Podolski resigned .Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately.  Full Article

FDA Advisory Committee discusses clinical trial designs for obesity-related hypogonadism
Tuesday, 6 Dec 2016 08:01pm EST 

Repros Therapeutics Inc : Says intends to meet with FDA to discuss design of a definitive phase 3 study that incorporates advice of committee .FDA Advisory Committee discusses clinical trial designs for obesity-related hypogonadism.  Full Article

Repros says groups showed improvement in Enclomiphene study
Monday, 15 Aug 2016 04:01pm EDT 

Repros Therapeutics Inc : Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men .All groups showed statistically significant improvement in all metabolic parameters tested..  Full Article

Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million
Tuesday, 9 Aug 2016 04:25pm EDT 

Repros Therapeutics Inc :Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million.  Full Article

Repros Therapeutics Inc. reported Q2 EPS ($0.18)
Tuesday, 9 Aug 2016 09:15am EDT 

Repros Therapeutics Inc : Repros Therapeutics Inc. reports second quarter 2016 financial results .Q2 loss per share $0.18.  Full Article

Repros Therapeutics reports Q1 loss per share of $0.20
Tuesday, 10 May 2016 09:15am EDT 

Repros Therapeutics Inc : Repros therapeutics inc.® reports first quarter 2016 financial results .Q1 loss per share $0.20.  Full Article

Repros Therapeutics Inc announces acceptance for filing of NDA
Wednesday, 1 Apr 2015 04:01pm EDT 

Repros Therapeutics Inc:Says new drug application for its enclomiphene citrate product candidate, formerly known as Androxal, has been accepted by U.S. Food and Drug Administration, indicating that application is sufficiently complete to permit a substantive review.Says this investigational product, which is company's lead product candidate, is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound.Says is developing this product candidate for treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.Says men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile.  Full Article

More From Around the Web

BRIEF-Repros announces new CEO

* Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately Source text for Eikon: Further company coverage: